Golshani, Shiva, Faramarzi, Mohammad Ali. (1400). Expected Impact of Biosimilars on the Pharmaceutical Companies. سامانه مدیریت نشریات علمی, 46(5), 399-401. doi: 10.30476/ijms.2021.92314.2356
Shiva Golshani; Mohammad Ali Faramarzi. "Expected Impact of Biosimilars on the Pharmaceutical Companies". سامانه مدیریت نشریات علمی, 46, 5, 1400, 399-401. doi: 10.30476/ijms.2021.92314.2356
Golshani, Shiva, Faramarzi, Mohammad Ali. (1400). 'Expected Impact of Biosimilars on the Pharmaceutical Companies', سامانه مدیریت نشریات علمی, 46(5), pp. 399-401. doi: 10.30476/ijms.2021.92314.2356
Golshani, Shiva, Faramarzi, Mohammad Ali. Expected Impact of Biosimilars on the Pharmaceutical Companies. سامانه مدیریت نشریات علمی, 1400; 46(5): 399-401. doi: 10.30476/ijms.2021.92314.2356
Expected Impact of Biosimilars on the Pharmaceutical Companies
1Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
2Department of Drug and Food Control, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
چکیده
In the last three decades, biological products have gradually developed to be an essential basis in the pharmaceutical industry. Advancements in this field have encouraged the frontiers of science to bring life-saving treatments to patients suffering from incurable diseases, such as cancers and has also assisted clinicians in managing chronic diseases e.g., rheumatoid arthritis.
Biosimilars Council [Internet]. Why biosimilar are important for patients. [Accessed July 20, 2021]. Available from: https://biosimilarscouncil.org/resource/why-biosimilars-are-important-for-patients
Malipatil NB, Haridas K, Prithvi SD. An overview of biosimilars. Asian Journal of Pharmaceutical and Clinical Research. 2015;8:23-7.
Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Narayanan G, et al. Biosimilars-why terminology matters. Nat Biotechnol. 2011;29:690-3. doi: 10.1038/nbt.1936. PubMed PMID: 21822237.
Vamseedhar Naik B, Lokesh Reddy M, Haranadh CH, Sabareesh M, Umasankar K. A review on biosimilar drugs. IJRPNS. 2014;3:153-58.
What are biosimilars and are they important? Drug Ther Bull. 2013;51:57-60. doi: 10.1136/dtb.2013.5.0181. PubMed PMID: 23657197.
European Union [Internet]. European Medicines Agency, European Commission. Biosimilars in the EU. [Accessed July 20, 2021]. Available from: https://www.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648
Zarbin M. The Development Pathway for Biosimilar Biotherapeutics. J Ophthalmic Vis Res. 2020;15:273-4. doi: 10.18502/jovr.v15i3.7444. PubMed PMID: 32864056; PubMed Central PMCID: PMCPMC7431720.
FISH [Internet]. Biosimilars 2020 year in review. [Accessed July 20, 2021]. Available from: https://www.fr.com/biosimilars-2020-year-in-review
Market reports/biosimilars. [Accessed July 20; 2021]. Available from: https://www.marketsandmarkets.com
How to compete and win in a world with biosimilars. [Accessed July 20; 2021]. Available from: http://assets.Kpmg/content/dam kpmg/pdf/2015/10/world of biosimilars.Pdf
Abu Zafor Sadek MD. Global status of biosimilars and its influential factors. European Journal of Business and Management Research. 2020;5:1-6. doi: 10.24018/ejbmr.2020.5.6.565.
Winning with biosimilars Opportunities in global markets. [Accessed July 20; 2021]. Available from: http://www2.deloitte.com/content/dam/Deloitte/us/Documents/life-science-health-care/us-lshc-biosimilars-whitepaper.pdf
Biosimilar Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026. [Accessed July 20; 2021]. Available from: https://www.imarcgroup.com/biosimilar-market